Dyne Therapeutics, Inc. (NASDAQ: DYN) has announced the pricing of an underwritten public offering of 24,242,425 shares of its common stock at a public offering price of $8.25 per share. This pricing is expected to result in gross proceeds of $200.0 million, before deducting underwriting discounts and commissions as well as offering expenses payable by Dyne.
All shares in the offering are being sold by Dyne, with the offering expected to close on or about July 2, 2025, subject to customary closing conditions. Additionally, Dyne has granted the underwriters a 30-day option to purchase up to an additional 3,636,363 shares of its common stock at the public offering price, less the underwriting discounts and commissions.
Joint book-running managers for the offering are Morgan Stanley, Jefferies, Stifel, and Guggenheim Securities, with Jones acting as co-manager for the offering.
This offering is being made pursuant to a shelf registration statement on Form S-3 that was previously filed with the Securities and Exchange Commission (SEC) on March 5, 2024, and became automatically effective upon filing. It will be conducted by means of a prospectus supplement and accompanying prospectus that form a part of the registration statement.
Dyne Therapeutics is focused on delivering functional improvement for people living with genetically driven neuromuscular diseases. The company is developing therapeutics that target muscle and the central nervous system to address the root causes of diseases. They are advancing clinical programs for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD), and preclinical programs for facioscapulohumeral muscular dystrophy (FSHD) and Pompe disease. Today the company's shares have moved -8.82% to a price of $8.68. Check out the company's full 8-K submission here.
